enGene Therapeutics Inc.
No SEC Form 4 filings for $ENGN in the last 30 days.
See all $ENGN insider activity →Analyst estimates for enGene Therapeutics Inc. show its average 12-month price target was cut from $3.50 to $3.43, with a range of $2 to $5 per share. Based on the Aug. 14 close, the target implies about 102% upside. The consensus rating remains “Hold” with 4 Buys, 5 Holds, and 1 Sell.
enGene Therapeutics (Nasdaq: ENGN) announced board changes, with Michael Heffernan becoming Chairman and Dr. Richard Glickman stepping down. The company plans a 2H 2026 FDA Pre-BLA meeting and BLA submission for detalimogene, targeting potential FDA approval in 2027. Detalimogene is in Phase 2 LEGEND for high-risk BCG-unresponsive NMIBC.
enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001980845 00-0000000 0001980845 us-gaap:CommonStockMember 2026-07-15 2026-07-15 0001980845 2026-07-15 2026-07-15 0001980845 us-gaap:WarrantMember 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursu
Over the past 7 days, alphai's AI scored 1 news story mentioning ENGN (enGene Therapeutics Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ENGN coverage spans financial news, corporate actions and earnings.
The article is a consensus price-target cut with unchanged “Hold” rating, implying limited near-term catalyst from analysts alone.
Board chair transition plus a defined FDA timeline increases near-term catalyst visibility into 2H 2026 and 2027 approval optionality.
Board leadership change may affect governance optics and near-term investor sentiment, but the filing provides no operational or financial guidance.
The restructuring signals cash preservation and operational downsizing, typically negative short-term but can stabilize runway.
Clinical interim efficacy/safety readout plus explicit 2H 2026 BLA timing and cost-cutting actions can reprice probability-weighted regulatory/commercial outcomes.
alphai scores every news story that mentions ENGN with an AI model for sentiment and relevance, and aggregates insider trades from enGene Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analyst estimates for enGene Therapeutics Inc. show its average 12-month price target was cut from $3.50 to $3.43, with a range of $2 to $5 per share. Based on the Aug. 14 close, the target implies about 102% upside. The consensus rating remains “Hold” with 4 Buys, 5 Holds, and 1 Sell.
1 min readenGene Therapeutics (Nasdaq: ENGN) announced board changes, with Michael Heffernan becoming Chairman and Dr. Richard Glickman stepping down. The company plans a 2H 2026 FDA Pre-BLA meeting and BLA submission for detalimogene, targeting potential FDA approval in 2027. Detalimogene is in Phase 2 LEGEND for high-risk BCG-unresponsive NMIBC.
4 min readenGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001980845 00-0000000 0001980845 us-gaap:CommonStockMember 2026-07-15 2026-07-15 0001980845 2026-07-15 2026-07-15 0001980845 us-gaap:WarrantMember 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursu
3 min readBiotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.
6 min readenGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 engn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 enGene Reports Second Quarter 2026 Financial Results and Provides Business Update 12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Ap
6 min readenGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001980845 00-0000000 0001980845 us-gaap:CommonStockMember 2026-06-09 2026-06-09 0001980845 2026-06-09 2026-06-09 0001980845 us-gaap:WarrantMember 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursu
2 min readAntengene (SEHK:6996) said it will present first preclinical data on ATG-207, a CD3-TGF-bifunctional fusion protein, at EULAR 2026 in London (June 3–6). The poster (POS-1110, June 6) reports preferential TGFRIII binding, TCR downregulation, regulatory T-cell induction and efficacy in an EAE mouse model, with lower proinflammatory cytokine release versus a CD3-TGF control, according to the abstract.
3 min readenGene Holdings Inc. (NASDAQ:ENGN) experienced a 17.7% decrease in short interest during February, settling at 1,235,753 shares, representing 2.1% of shares outstanding. The short-interest ratio for the clinical-stage biopharmaceutical company is now 10.4 days. Analysts maintain a "Moderate Buy" rating with an average target price of $22.86, following recent broker activity including buy/outperform calls and a $30 target from Oppenheimer.
3 min readenGene (NASDAQ:ENGN) shares surged 11.3% on Thursday, trading at $10.39 with significantly higher volume than average. Analysts currently rate ENGN as a "Moderate Buy" with an average price target of $22.38, though individual ratings range from a "strong-buy" to a "sell." Despite missing quarterly EPS estimates, the clinical-stage gene-therapy company, which uses the EDV platform, maintains strong liquidity and low debt levels.
3 min readU.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Tuesday. The Dow traded up 0.64% to 47,673.48 while the NASDAQ fell 0.79% to 23,340.59. The S&P 500 also fell, dropping, 0.23% to 6,817.03. Energy shares jumped by 1.2% on Tuesday.
3 min read
